Published October 2024
Below is a recap of the Pharmacy Policies that went into effect recently. All policies are reviewed at least once annually. For more detailed information on these changes, please review 2024 FastFaxes or visit all policies here.
Drugs removed from prior authorization for Commercial, Marketplace, and Self-Funded Formularies
- Airsupra
- Olpruva
- Rezzayo
- Xacduro
- Vanflyta
- Akeega
- Jesduvroq
- Pokonza
- Motpoly XR
- Likmez
- Fruzaqla
- Truqap
- Augtyro
- Ogsiveo
- Balfaxar injection
- Rykindo
- Brixadi
New Drugs excluded for Commercial, Marketplace, and Self-Funded Formularies
- Veozah
- Sogroya
- Uzedy
- Zavzpret
- Inpefa
- Miebo
- Ngenla
- Suflave
- Xdemvy
- Skytrofa
- Brenzavvy
- Entyvio pen
- Velsipity
- Bimzelx
- Omvoh IV infusion
- Omvoh SQ pen
- Xphozah
- Inpefa
- Vevye
- zoryve foam
New generics that recently came to market
| Brand Name | Generic Name |
|---|---|
| Farxiga | Dapagliflozin |
| Xigduo XR | Dapagliflozin-Metformin |
| Prolensa | Bromfenac ophthalmic solution |
| Indocin | Indomethacin suspension |
| Korlym | Mifepristone |
| Gralise | Gabapentin ER |
| Emflaza | Deflazacort |
| Rectiv ointment | Nitroglycerin ointment 0.4% |
| Bromsite | Bronfenac ophthalmic 0.075% |
| Alrex suspension | Lotepredol ophthalmic |
| Thiola EC | Tiopronin tab delayed release |
| Lithium solution | Lithium oral solution |
| Estrogel | Estradiol gel |
| Myrbetriq | Mirabegron |
| Orfadin capsules | Nitisinone |
| Halaven | Eribulin inj |
| Relexxii | Methylphenidate OSM ER |
| Somatuline | Lanreotide ER inj |
| Victoza | Liraglutide |